The tablets are disappearing from shelves across the South Metro. For anyone who has been taking them daily, the harder question is what happens to your body on the morning the last box runs out.
Medically reviewed by Dr. Ajibola Babatunde, MD
Where this stands as of August 11, 2026. Georgia’s Kratom Consumer Protection Act has been in effect since January 1, 2025, and already caps how much 7-OH a legal product may contain. On July 6, 2026, the Drug Enforcement Administration published notices of intent to temporarily place concentrated 7-OH, along with three lab-made relatives, into Schedule I. That federal process is underway and not yet final. Last verified: August 11, 2026.
The tablets sit behind the counter at the gas station on Highway 54, in a little locked display by the register, somewhere between the phone chargers and the energy shots. Bright foil. A number printed on the front. Somebody in Fayetteville picks up a two-pack on the way to work most mornings, has done it for a year, and has never once used the word “drug” about it.
That shelf is going empty. The ban itself will not hurt anyone. What will hurt people is the month after it lands, when a lot of quiet daily dependencies turn into forced, unplanned withdrawal at roughly the same time, in bedrooms and parked cars instead of in a treatment setting. If you take 7-OH daily, or you love somebody who does, the useful thing to understand right now is what your body will do when the supply stops.
What 7-OH Actually Is, and Why “Kratom” Is the Wrong Word for It
Almost everyone taking these products calls them kratom. That is what the packaging says, and it is the most expensive misunderstanding in this whole story, because it makes a potent opioid sound like a tea.
Kratom is a tree, Mitragyna speciosa, that grows in Southeast Asia. Its leaves contain dozens of compounds. The main one is mitragynine. 7-hydroxymitragynine, shortened to 7-OH, is a minor one. In the actual leaf, the Drug Enforcement Administration describes 7-OH as making up less than two percent of total alkaloid content, often occurring only in trace amounts. The FDA describes it the same way, and has said plainly that its warnings target products where 7-OH has been added or boosted, not plain leaf.
The products behind the counter are a different thing. 7-OH can be made from mitragynine in a single chemical step, and the DEA notes that lab-made and plant-made 7-OH are chemically identical, so the body cannot tell them apart. Manufacturers isolate it, concentrate it, or synthesize it outright, then press it into tablets, capsules, gummies, drink mixes, shots, and dissolving films built for fast absorption. Whole leaf comes packaged with competing compounds that blunt its effect. Isolated 7-OH arrives with nothing in the way.
There is a further tier most buyers have never heard of. Alongside 7-OH, the DEA moved on three lab-made relatives: mitragynine pseudoindoxyl, sometimes labeled MP, plus MGM-15 and its more potent sibling MGM-16. None occurs naturally in the plant. In animal studies cited by the DEA, MGM-15 measured roughly 50 times the potency of morphine and MGM-16 roughly 240 times. They sell in the same coolers, in the same packaging, under the same word.
Where the Law Stands in Georgia, and Where It Is Headed Nationally
Georgia did not wait for Washington. If you have been buying these products in Fayette or Coweta County and assumed nobody was looking, the state has been regulating them for more than a year and a half.
What Georgia Law Already Requires
Georgia’s Kratom Consumer Protection Act took effect on January 1, 2025. Under O.C.G.A. § 16-13-122, as summarized by the Georgia Attorney General’s office, a kratom product sold in or delivered to Georgia may not exceed:
- 150 mg of mitragynine per serving. A cap on the plant’s main compound.
- 0.5 mg of 7-OH per gram. A concentration limit, measured by weight.
- 1 mg of 7-OH per serving. The ceiling most high-dose tablets on the market blow straight past.
The same law bans synthetic alkaloids outright, including synthetic 7-OH. It requires buyers to be at least 21, requires products to sit behind the counter or in a display an employee has to open, requires the milligram amounts to be printed on the label, and prohibits selling kratom in any form meant to be vaped.
On November 13, 2025, Attorney General Chris Carr issued a consumer alert about 7-OH specifically, describing products “flooding gas stations, vape shops, and convenience stores,” often designed to look like candy, gummies, or ice cream cones. That alert, citing the FDA, put concentrated 7-OH at roughly 13 times the potency of morphine.
What the Federal Government Did in July 2026
In July 2025, the FDA recommended that 7-OH be placed in Schedule I. A year later the machinery moved. On July 6, 2026, the DEA published two notices of intent in the Federal Register: one to temporarily schedule 7-OH above a threshold of 0.050 percent by weight, and one covering mitragynine pseudoindoxyl, MGM-15, and MGM-16. Health and Human Services opened a 30-day public comment period the same week.
Two details matter locally. The agencies have stated these actions target concentrated and synthetic products, not natural leaf carrying only trace 7-OH. And the DEA has said its threshold does not override stricter state law, so Georgia’s 1 mg per serving cap stands regardless of where the federal process lands.
The Bill That Would Change All of This
There is a further step under consideration in Georgia, and it would go considerably beyond both the state law described above and the federal notices. House Bill 968, carried by Representatives Townsend of the 179th, Stephens of the 164th, Williams of the 148th, Smith of the 18th, and Corbett of the 174th, proposes two things. It would add to Georgia’s Schedule I any material, compound, mixture, or preparation containing any quantity of mitragynine or hydroxymitragynine, including their salts and isomers. And it would repeal the Kratom Consumer Protection Act in its entirety.
The difference matters if you currently buy kratom legally in Georgia. The federal notices draw a line at concentration, deliberately leaving natural leaf with only trace 7-OH outside their scope. HB 968 as introduced draws no such line. Mitragynine is the primary alkaloid in ordinary kratom leaf, so the bill would place plain kratom in the same schedule as heroin, and would remove the framework that currently keeps products behind the counter, capped, labeled, and away from anyone under 21.
Treat this as proposed legislation rather than settled law. A committee substitute was reported in March 2026, which means the operative text may differ from the version introduced, and bills change or die at every stage. Anyone making a decision on the strength of it should confirm the current status directly with the Georgia General Assembly rather than relying on this page, or on any page.
Why 7-OH Is Not a Safer Alternative to Opioids
Most people did not go looking for an opioid. They went looking for something legal that would get them through a shift, or let them sleep, or stop them being sick, and a clerk or a coworker or a forum pointed them here. Nobody reading this needs to be scolded. But the pharmacology has to be said straight, because decisions are being made on bad information.
7-OH is an opioid. The DEA describes it as having opioidergic activity with a pharmacological profile similar to Schedule II opioids like morphine, meaning it lands on the same receptors that morphine and oxycodone land on. Preclinical data show the same tolerance, the same dependence, and the same respiratory depression, which is the slowing of breathing that makes an opioid overdose fatal.
Here are the beliefs that come up most in intake conversations, and what the evidence says.
“It’s herbal, so it’s basically a plant.”
The molecule in a high-dose tablet is frequently made in a lab, and where it is pulled from the plant it has been concentrated far past anything the leaf produces. Your receptors respond to the molecule, not to the origin story on the box.
“It’s a step down from pills.”
By potency it is a step sideways or up. The Attorney General’s alert, citing the FDA, puts concentrated 7-OH at about 13 times morphine’s potency, and the lab-made relatives measure higher still in animal studies.
“It’s legal, so somebody must be checking it.”
The FDA has approved no 7-OH product for any medical use, and it is not lawful as a dietary supplement or a food additive. The DEA notes no controlled clinical trials have established a safe dose, and that purity, identity, and quantity in these products are frequently unknown.
“I can control the dose.”
The high is short. Users consistently report an urge to redose, and describe 7-OH as lacking the nausea ceiling that limits how much plain leaf a person can physically take. That combination is how daily use climbs without anyone deciding to let it.
“It Helped Me Get Off Opioids”
This one deserves more respect than it usually gets. It is often true, and it is not naive. Kratom has been used for generations as an opium substitute and to blunt opioid withdrawal, and the FDA acknowledges people reach for 7-OH specifically to manage withdrawal, pain, and anxiety. If you used it to get off heroin or pills and it worked, something real happened. You are not a fool and you did not fail.
The problem is what kind of win it is. Because 7-OH is itself an opioid, it relieves opioid withdrawal the way another opioid does, so the dependence moved rather than ended. People who arrive at detox this way often describe feeling ashamed twice over, once for the original use and once for ending up dependent on the thing that was supposed to be the exit. That is not a character flaw. It is what happens when an opioid is sold as a supplement.
One Piece of this is Genuinely Good News
Because 7-OH acts on opioid receptors, naloxone reverses a 7-OH overdose. The DEA’s filing cites a 2026 case in which a patient in cardiopulmonary arrest was revived with naloxone after using 7-OH. If there is a daily 7-OH user in your house, naloxone belongs in the medicine cabinet, and the Georgia Poison Center answers around the clock at 1-800-222-1222.
What 7-OH Withdrawal Actually Is
It is opioid withdrawal. Not a caffeine crash, not a rough couple of days, not something willpower settles. People who have been through both usually say 7-OH withdrawal arrived faster and hit harder than they expected from something bought at a gas station.
Published research on 7-OH withdrawal specifically is still thin, so an honest description covers the shape rather than a stopwatch. Onset tends to be quick, because the effect is short-acting and dosing is frequent. The acute stretch is intense. Then comes a tail of poor sleep, low mood, and cravings that can run well past the point where visible symptoms have cleared. For the general opioid withdrawal picture, the clinical literature summarized in StatPearls lists watering eyes and runny nose, goosebumps, muscle and bone aches, stomach cramping, diarrhea, nausea, dilated pupils, light sensitivity, insomnia, yawning, sweating, and a racing heart with rising blood pressure. The FDA’s reports on 7-OH products name restlessness, body aches, fatigue, irritability, cold sweats, insomnia, and seizures.
Anyone wanting a fuller picture will find that kratom withdrawal follows a recognizable arc, and that the broader opioid withdrawal timeline maps closely onto what 7-OH does. The point of a timeline is not to brace for it. It is to know which parts are dangerous and which parts are merely miserable, because those call for different responses.
The Supply Shock Nobody Is Planning For
Here is the part missing from the coverage. When a substance leaves the shelves, people who depend on it do not sit down and write a taper schedule. They stop when the last box runs out. The date gets set by a distributor, not a doctor, and it lands on a Tuesday in the middle of a work week.
Two patterns show up whenever this happens. The first is stockpiling. A clearance sale feels like a solution, and buying six months of product only postpones the problem. It does not remove it. It relocates the same withdrawal to a later date, usually a worse one, usually with nobody nearby who knows what is happening. The second pattern is more dangerous: someone in unmanaged opioid withdrawal starts looking for anything that will stop the sickness, and in South Metro Atlanta what is easiest to find is a counterfeit pill that may contain fentanyl. Tolerance drops fast during withdrawal, which is precisely why that substitution kills people.
If that sounds like a plan already forming in your head, or in the head of someone you have been watching closely, this is the window. A withdrawal that is scheduled and supervised is a fundamentally different event from a withdrawal that happens to you.
Why Medical Detox Beats a Kitchen-Table Taper
Plenty of people taper off substances at home successfully. The reason for caution here is that 7-OH’s own case reports point the other way. The DEA’s filing cites a 2025 case of a 38-year-old man with severe 7-OH dependence who required inpatient buprenorphine stabilization to get through withdrawal. When the published literature on a substance is thin and the cases that made print are the ones that needed a hospital, that is worth weighting.
Some situations make self-managed withdrawal a genuinely poor bet:
- High daily doses or long-running use. The larger the daily amount and the longer the run, the steeper the drop, and the less a gradual reduction can be improvised without a scale, a schedule, and clinical eyes.
- A previous withdrawal that went badly. If a past attempt brought seizures, uncontrolled vomiting, or an ER visit, that history is data. Seizure risk during kratom-family withdrawal is not theoretical.
- Alcohol or benzodiazepines in the mix. This one changes everything. Withdrawal from alcohol or benzodiazepines can itself be fatal, unlike opioid withdrawal, which is usually survivable while feeling unsurvivable. Stopping everything at once at home is how people have seizures alone. Alcohol detox and benzodiazepine detox each need medical supervision in their own right.
- Co-occurring depression, anxiety, PTSD, or bipolar disorder. Withdrawal amplifies whatever is already there. When mood symptoms and substance use feed each other, both need treating at the same time rather than in sequence.
Medication matters here too, and it is where the most dangerous internet advice lives. Buprenorphine, the active medication in Suboxone, attaches to the same receptors 7-OH uses, holds on far more tightly, and switches them on only partially. Given while a large amount of 7-OH is still attached, it can shove the 7-OH aside and replace a strong signal with a weaker one. The body reads that as instant, total withdrawal, and it can arrive within minutes. Clinicians call it precipitated withdrawal.
It is preventable, and preventing it is a timing judgment that depends on your dose, how long you have used, what else is in your system, and how you actually feel when the first dose is offered. That is a prescriber’s decision, made with your history in front of them. A number written for a general audience cannot account for any of it. Medication-assisted treatment works well for opioid dependence, and it works when the induction is timed by someone watching you.
Getting Off 7-OH Safely in Fayetteville
Peachtree Detox sits at 1008 GA-54 in Fayetteville, on the same highway as a fair number of the stores that have been selling these products, about half an hour south of the airport and within easy reach of Peachtree City, Tyrone, Newnan, Jonesboro, and Griffin. We provide medical detox and residential treatment for substance use disorder for adults 69 and under, with clinical monitoring around the clock while withdrawal is active and physician oversight of the medications used to manage it. Our kratom and 7-OH detox program treats this as what it is, an opioid withdrawal, and our medication options include Suboxone, Sublocade, Vivitrol, and naltrexone where clinically appropriate.
What happens after the acute days decides whether this holds: weekly individual therapy with a master’s-level therapist, CBT and DBT, trauma-informed care, and family therapy for the people who have been carrying this alongside you. Phones are available nightly, the most open policy in our network, which matters more than it sounds like it should when someone has kids at home or a job to hold together.
We are in-network with Tricare East, Select and Prime. If you carry a different plan, we will verify your benefits and tell you plainly what your policy actually covers before you commit to anything.
If you are the one taking these tablets, needing help to stop does not mean you failed at quitting. Or, if you are the parent or partner who found the empty foil packets and has been quietly reading about this at odd hours, you are not overreacting. Start with our admissions team whenever you are ready. If you are not ready today, keep this and come back to it. We will meet you with the same respect whenever you reach out.
Frequently Asked Questions About 7-OH Bans and How To Get Help
There is no reliable published timeline specific to 7-OH yet, and anything giving you exact hours is guessing. What clinicians see follows the general opioid withdrawal pattern: onset is fast because 7-OH is short-acting and taken frequently, the acute phase is intense over the first several days, and a tail of disrupted sleep, low mood, and cravings can persist for weeks. Daily dose, how long you have used, and whether alcohol, benzodiazepines, or other opioids are also involved change the picture substantially, which is why an assessment gives you a far more useful answer than a chart.
There is no way to stop a daily opioid and feel nothing, and anyone promising that is selling something. There is a large difference between unmanaged withdrawal and medically managed withdrawal. In a detox setting, medications can blunt the nausea, cramping, restlessness, and sleeplessness, fluids and monitoring handle the physical risk, and the medications used for opioid dependence can be started under supervision. Most people describe supervised withdrawal as difficult but tolerable, rather than the experience they were dreading.
Buprenorphine, the medication in Suboxone, is used for opioid dependence, and 7-OH is an opioid, so it is a recognized option. The timing question is the dangerous part. Buprenorphine binds to the same receptors more tightly than 7-OH does while activating them only partially, so taking it too early can displace the 7-OH and trigger sudden, severe precipitated withdrawal. The right timing depends on your dose, how long you have used, what else is in your system, and your symptoms at that moment. That is a decision for a prescriber examining you, not a number to take from a website.
They are not the same thing, and the labeling blurs it deliberately. Kratom is a plant whose leaves contain 7-OH in trace amounts. The products driving the current concern contain 7-OH that has been isolated, concentrated, or made in a lab, sometimes alongside synthetic relatives like MGM-15 that never occur in the plant at all. Kratom leaf can produce dependence and withdrawal. Concentrated 7-OH does so faster and harder, because it delivers an opioid-strength dose without the plant’s other compounds moderating it.
Sources
- Georgia Office of the Attorney General. (2025, November 13). Consumer alert: Carr warns of dangerous synthetic opioids flooding gas stations. Retrieved from: https://law.georgia.gov/press-releases/2025-11-13/consumer-alert-carr-warns-dangerous-synthetic-opioids-flooding-gas. Accessed on August 25, 2026.
- Drug Enforcement Administration. (2026, July 6). Schedules of controlled substance: Temporary placement of 7-hydroxymitragynine above a specified threshold in schedule I. 91 FR 40917. Federal Register. Retrieved from: https://www.federalregister.gov/documents/2026/07/06/2026-13580/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-above-a-specified. Accessed on August 25, 2026.
- Drug Enforcement Administration. (2026, July 6). Schedules of controlled substances: Temporary placement of mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I. 91 FR 40909. Federal Register. Retrieved from: https://www.federalregister.gov/documents/2026/07/06/2026-13581/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and. Accessed on August 25, 2026.
- U.S. Food and Drug Administration. (2026, July 13). Hiding in plain sight: 7-OH products. Retrieved from: https://www.fda.gov/news-events/public-health-focus/hiding-plain-sight-7-oh-products. Accessed on August 25, 2026.
- U.S. Food and Drug Administration. (n.d.). Products containing 7-OH can cause serious harm. Retrieved from: https://www.fda.gov/consumers/consumer-updates/products-containing-7-oh-can-cause-serious-harm. Accessed on August 25, 2026.
- U.S. Food and Drug Administration. (2025). FDA takes steps to restrict 7-OH opioid products threatening American consumers. Retrieved from: https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers. Accessed on August 25, 2026.
- National Institute on Drug Abuse. (n.d.). Kratom. Retrieved from: https://nida.nih.gov/research-topics/kratom. Accessed on August 25, 2026.
- Shah, M., & Huecker, M. R. (2023). Opioid withdrawal. StatPearls. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK526012/. Accessed on August 25, 2026.
- National Institute on Drug Abuse. (n.d.). Naloxone DrugFacts. Retrieved from: https://nida.nih.gov/publications/drugfacts/naloxone. Accessed on August 25, 2026.
